Team successfully deploys MHS GENESIS to 18 additional military commands in latest wave
RESTON, Go., October 10, 2022 /PRNewswire/ — The Leidos Partnership for Defense Health (LPDH) today announced that it has successfully delivered the MHS GENESIS electronic health record to an additional 10,000 clinicians and providers as part of its latest dual wave deployment. (Waves JACKSONVILLE/EGLIN), covering 18 new military processing facility commands in Alabama, Florida, Georgia, Tennessee, Mississippi and Caroline from the south. The latest revenue cycle functionality integrates new patient accounting, medical coding and patient registration/access functionality into the existing MHS GENESIS system.
“The Revenue Cycle is a fully integrated platform that will replace paper-based practices and introduce a new clinic-focused patient accounting system, including medical coding software and a comprehensive billing database for the system. of military health,” said Liz Porter, chairman of Leidos Health Group. “This new capability will improve communication between the clinical and commercial communities while providing insight into overall costs of care and preparation.”
LPDH designed and developed MHS GENESIS, the new Electronic Health Record for the Military Health System, and has been providing program management and technical expertise to the Defense Health Care Management Systems (PEO DHMS) Program Executive Office since 2015.
The MHS GENESIS system is now operational at more than 1,800 sites and reaches 5.1 million DOD beneficiaries, approximately 67% of whom are deployed.
“The revenue cycle capability includes Electronic Data Interchange (EDI) support with an updated front-end patient identification and registration process,” noted Holly Joers, PEO DHMS. “The MHS GENESIS System continues to leverage commercial best practices to help improve clinical outcomes with each deployment. The program is on schedule with eight additional deployments planned through the end of 2023.”
MHS GENESIS is being rolled out across the continent United States and overseas through a total of 23 waves. Each wave will target a specific region over a year, with an average of three hospitals and many physical locations for each wave. This approach allows DOD to take full advantage of lessons learned from previous waves to maximize the effectiveness of subsequent waves. The DOD plans to complete full deployment of MHS GENESIS to garrison facilities by the end of calendar year 2023.
Leidos is a Fortune 500® technology, engineering, and scientific solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, civilian, and healthcare markets. The company’s 44,000 employees support vital missions for government and commercial customers. Based at Reston, VirginiaLeidos recorded annual revenues of approximately $13.7 billion for the year ended December 31, 2021. For more information, visit www.Leidos.com.
The Leidos partnership consists of four main partners – Leidos, Oracle Cerner Corporation, Accenture and Henry Schein One – with about 35 supporting companies. Together, they provide an integrated, modern, and secure health information system that includes an electronic health record system, dental system, identity management capability, cybersecurity, and other supporting components. MHS GENESIS will serve as the system of record, providing a single, integrated solution to manage military force health and readiness for DOD and the Department of Veterans Affairs.
Certain statements contained in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the United States Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or events. A number of factors could cause our actual industry results, performance, achievements or results to differ from the results, performance or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the year ended December 31, 2021, and other similar filings that Leidos makes from time to time with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events occurring after the date on which the forward-looking statements were made.
lemon balm Duenas